YU64699A - Kvaternarna jedinjenja amonijuma kao tahikininski antagonisti - Google Patents
Kvaternarna jedinjenja amonijuma kao tahikininski antagonistiInfo
- Publication number
- YU64699A YU64699A YU64699A YU64699A YU64699A YU 64699 A YU64699 A YU 64699A YU 64699 A YU64699 A YU 64699A YU 64699 A YU64699 A YU 64699A YU 64699 A YU64699 A YU 64699A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- alkyl
- fluoro
- alkoxy
- cycloalkyl
- optionally substituted
- Prior art date
Links
- 102000003141 Tachykinin Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108060008037 tachykinin Proteins 0.000 title abstract 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- -1 benzo[b]thienyl Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Predmetni pronalazak se odnosi na jedinjenje formule: gde R je fenil, C3-C7 cikloalkil ili heteroaril, svaki po izboru benzo- ili C3-C7-cikloalkil fuziran i po izboru supstituisan, koji ukljucuju u benzo- ili C3-C7-cikloalkil-fuziranom delu od 1 do 3 supstituenta od kojih se svaki nezavisno bira iz grupe koja obuhvata C1-C4 alkil, fluoro (C1-C4) alkil, C1-C4alkoksi, fluoro (C1-C4) alkoksi, fenoksi, C2-C4 alkanoil, halo C1-C4alkoksikarbonil, C3-C7 cikloalkil, -S(O)m(C1-C4 alkil), ciano, -NR2R3, -S(O)mNR2R3, -NR4(C1-C4alkanoil) i -CONR2R3 ili R je 2,3-dihidrobenzo[b]furanil ili hromanil; R1 je H ili C1-C6 alkil; W je direktna veza, metilen ili etilen; X je neracvast C2-C4 alkilen; Y je fenil, naftil, benzil, piridil, tienil ili C3-C7 cikloalkil od kojih je svaki po izboru supsstituisan sa 1 do 3 supstituenta koji se svaki nezavisno bira iz grupe koja obuhvata C1-C4 alkil, fluoro C1-C4 alkil, C1-C4 alkoksi, fluoro C1-C4 alkoksi, halo i ciano, ili Ar je 1,3-benzodioksolan-4, ili 5-il ili 1,4-benzodioksan-5 ili 6-il; ZA je farmaceutski prihvatljiv anjon; uz predpostavku da kada W je direktna veza i R je po izboru fuziran i po izboru supstituisan heteroaril, pomenuti heteroaril je vezan pomocu ugljenicnog atoma prstena na karbonilnu grupu. Jedinjenja su tahikininski antagonisti.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712882.1A GB9712882D0 (en) | 1997-06-18 | 1997-06-18 | Quaternary ammonium compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU64699A true YU64699A (sh) | 2002-06-19 |
Family
ID=10814535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU64699A YU64699A (sh) | 1997-06-18 | 1998-06-05 | Kvaternarna jedinjenja amonijuma kao tahikininski antagonisti |
Country Status (43)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999033489A1 (fr) * | 1997-12-26 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales a liberation prolongee |
| JP4546589B2 (ja) * | 1998-04-23 | 2010-09-15 | 武田薬品工業株式会社 | ナフタレン誘導体 |
| NZ523310A (en) * | 2000-06-12 | 2005-07-29 | Univ Rochester | Tachykinin receptor antagonist to block receptors NK1, NK2, and NK3 and treat symptoms of hormonal variation |
| WO2002046156A2 (en) * | 2000-12-06 | 2002-06-13 | Sepracor, Inc. | 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands |
| AU2003243353A1 (en) * | 2002-05-29 | 2003-12-19 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| WO2005110998A1 (en) * | 2004-05-07 | 2005-11-24 | Janssen Pharmaceutica N.V. | Scalable synthesis of imidazole derivatives |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991201A (en) * | 1974-06-27 | 1976-11-09 | Janssen Pharmaceutica N.V. | 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents |
| US5583134A (en) * | 1992-09-30 | 1996-12-10 | Sanofi | 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present |
| FR2696178B1 (fr) * | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
-
1997
- 1997-06-18 GB GBGB9712882.1A patent/GB9712882D0/en active Pending
-
1998
- 1998-05-06 UA UA99126551A patent/UA62966C2/uk unknown
- 1998-05-19 TW TW087107720A patent/TW479055B/zh not_active IP Right Cessation
- 1998-06-04 HN HN1998000087A patent/HN1998000087A/es unknown
- 1998-06-04 PA PA19988452501A patent/PA8452501A1/es unknown
- 1998-06-05 CA CA002291975A patent/CA2291975C/en not_active Expired - Fee Related
- 1998-06-05 EP EP98932148A patent/EP0994876B1/en not_active Expired - Lifetime
- 1998-06-05 ID IDW991633A patent/ID23410A/id unknown
- 1998-06-05 TR TR1999/03135T patent/TR199903135T2/xx unknown
- 1998-06-05 WO PCT/EP1998/003500 patent/WO1998057972A1/en not_active Application Discontinuation
- 1998-06-05 PL PL98337713A patent/PL189557B1/pl not_active IP Right Cessation
- 1998-06-05 JP JP50368799A patent/JP3280993B2/ja not_active Expired - Fee Related
- 1998-06-05 HU HU0003962A patent/HUP0003962A3/hu unknown
- 1998-06-05 NZ NZ501286A patent/NZ501286A/xx unknown
- 1998-06-05 SK SK1744-99A patent/SK283346B6/sk unknown
- 1998-06-05 SI SI9830692T patent/SI0994876T1/xx unknown
- 1998-06-05 PT PT98932148T patent/PT994876E/pt unknown
- 1998-06-05 CN CNB988063425A patent/CN1199971C/zh not_active Expired - Fee Related
- 1998-06-05 AT AT98932148T patent/ATE275564T1/de not_active IP Right Cessation
- 1998-06-05 IL IL15562198A patent/IL155621A0/xx not_active IP Right Cessation
- 1998-06-05 DE DE69826129T patent/DE69826129T2/de not_active Expired - Fee Related
- 1998-06-05 YU YU64699A patent/YU64699A/sh unknown
- 1998-06-05 IL IL13307998A patent/IL133079A/en not_active IP Right Cessation
- 1998-06-05 EA EA199900986A patent/EA002424B1/ru not_active IP Right Cessation
- 1998-06-05 ES ES98932148T patent/ES2227856T3/es not_active Expired - Lifetime
- 1998-06-05 US US09/380,370 patent/US6207678B1/en not_active Expired - Fee Related
- 1998-06-05 KR KR1019997011931A patent/KR100345389B1/ko not_active IP Right Cessation
- 1998-06-05 BR BR9810619-8A patent/BR9810619A/pt not_active Application Discontinuation
- 1998-06-05 AU AU82153/98A patent/AU726027B2/en not_active Ceased
- 1998-06-08 PE PE1998000468A patent/PE80099A1/es not_active Application Discontinuation
- 1998-06-11 AP APAP/P/1998/001262A patent/AP947A/en active
- 1998-06-15 UY UY25045A patent/UY25045A1/es unknown
- 1998-06-16 MY MYPI98002689A patent/MY136376A/en unknown
- 1998-06-16 AR ARP980102853A patent/AR012249A1/es active IP Right Grant
- 1998-06-17 MA MA25118A patent/MA26509A1/fr unknown
- 1998-06-17 ZA ZA9805239A patent/ZA985239B/xx unknown
- 1998-06-17 DZ DZ980134A patent/DZ2524A1/xx active
- 1998-06-17 TN TNTNSN98089A patent/TNSN98089A1/fr unknown
- 1998-06-18 CO CO98034807A patent/CO4940478A1/es unknown
- 1998-06-18 HR HR980337A patent/HRP980337B1/xx not_active IP Right Cessation
-
1999
- 1999-11-23 IS IS5269A patent/IS5269A/is unknown
- 1999-11-23 BG BG103919A patent/BG63341B1/bg unknown
- 1999-11-25 NO NO995782A patent/NO995782L/no not_active Application Discontinuation
- 1999-12-15 OA OA9900281A patent/OA11235A/en unknown
-
2000
- 2000-12-11 US US09/734,266 patent/US6380396B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02003792A (es) | Moduladores de molecula pequena de receptores de serotonina endogenos constitutivamente activados. | |
| TW370451B (en) | Bicyclic amine derivatives | |
| UA48138C2 (uk) | 2-[(дигідро)піразоліл-3'-оксиметилен]-аніліди, спосіб їх одержання, проміжні сполуки, засіб та спосіб боротьби з сільськогосподарськими шкідниками та шкідливими грибами | |
| BG101196A (en) | 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides, method for preparing them and their use as pest-control agents | |
| KR100257619B1 (en) | Azole compounds, their production and use | |
| WO2003039451A3 (en) | Thiazole pyridazinones as adenosine antagonists | |
| MY147730A (en) | Metabotropic glutamate receptor antagonists | |
| SI1414302T1 (sl) | 7-aminotriazolopirimidini za nadzor ĺ kodljivih gljiv | |
| BG105666A (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex | |
| TW200738667A (en) | Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof | |
| NZ332658A (en) | Halo-substituted bis-indolylmaleimide derivatives and pharmaceutical compositions | |
| AP9600855A0 (en) | Insecticidal n-(substituted phenyl) methyl) piperidines | |
| WO2002028853A1 (fr) | Compose de benzylamine, son procede de production et produit intermediaire correspondant | |
| YU64699A (sh) | Kvaternarna jedinjenja amonijuma kao tahikininski antagonisti | |
| EP0945439A4 (en) | NEW AMINOPYRAZOLE DERIVATIVES | |
| EP0371805A3 (en) | Piperidine derivatives and hypotensives containing the same | |
| WO2001023392A8 (en) | Tetracyclic benzimidazole derivatives and combinatorial libraries thereof | |
| HUT75532A (en) | Diacyl-substituted guanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| BG103735A (en) | Method for the preparation of substituted thiazolidindions | |
| EP0335979A4 (en) | Thienopyrimidine derivatives | |
| AP2001002314A0 (en) | Substituted benzolactam compounds. | |
| EP1567508A4 (en) | 1,2,4-TRIAZOLE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
| AU4666289A (en) | Imidazolyl and pyridyl derivatives of phenyl substituted 1,4-dihydro-pyridines and process for their preparation | |
| ECSP982546A (es) | Compuestos de amonio cuaternario | |
| EP0651945A4 (en) | MEANS FOR PROTECTION FROM TERMITES. |